Travere Therapeutics Provides Corporate Update and 2024 Outlook
Received 459 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI totaled $15 million for the fourth quarter
Related news for (TVTX)
- Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
- Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
- Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
- Travere Therapeutics Provides Corporate Update and 2025 Outlook
- travere therapeutics reports third quarter 2024 financial results